Company Overview
Precision BioSciences, Inc. operates as a clinical stage gene editing company focused on developing in vivo gene editing therapies within the United States, specifically targeting gene edits that include insertion, excision, and elimination. The company functions within the Healthcare sector and the Biotechnology industry, positioning itself as a specialized developer of ARCUS, a genome editing platform capable of DNA genome insertion, removal, and repair. The firm currently maintains a market capitalization of $159.98M, generates annual revenue of $34.26M, and employs 68 individuals to execute its research and development objectives. These financial figures indicate a mid-cap biotechnology entity that has achieved significant revenue expansion while maintaining a relatively lean operational workforce, suggesting a capital-intensive growth model typical of the early-to-mid stages of biotechnology development where revenue scales rapidly to fund clinical trials and platform expansion.
Financial Health
The company reports a trailing twelve-month revenue of $34.26M alongside a net income of -$46,609,000 and an EBITDA of -$50,680,000, revealing a cost structure where operating expenses and R&D investments substantially exceed current revenue generation. This negative net income relative to revenue highlights the inherent burn rate of a clinical-stage enterprise investing heavily in platform development before reaching commercial profitability. Free cash flow stands at -$21,974,250, indicating that the company is currently burning cash, which implies a reliance on external capital markets or existing cash reserves to fund ongoing operations and pipeline progression. The firm holds $115.58M in cash against $28.81M in debt, supported by a debt-to-equity ratio of 31.23, presenting a balance sheet that appears conservative regarding leverage despite the negative earnings profile. Profit margins reflect the pre-commercial nature of the business, with a gross margin of 100.0% suggesting high-value intellectual property and low cost of goods sold, contrasted by an operating margin of 36.6% and a profit margin of -133.4% driven by the significant net loss. Liquidity is robust, evidenced by a current ratio of 13.32, which indicates the company possesses more than thirteen times the current assets necessary to cover its short-term liabilities without immediate distress. Return metrics show a return on equity of -62.7% and a return on assets of -22.4%, revealing that management is currently deploying capital to generate negative returns as the business scales its clinical pipeline rather than distributing profits.
Valuation Assessment
Valuation metrics for the company reflect its status as a loss-making growth entity, with a trailing P/E ratio of N/A and a forward P/E of -1.90, implying that traditional earnings-based valuation models are not yet applicable due to negative earnings and that the market is pricing in future potential rather than current profitability. The price-to-book ratio is recorded at 1.69, indicating that the market values the company at a 69% premium over its book value, which often occurs in biotechnology when investors assign high value to intangible assets like intellectual property and clinical data not fully captured on the balance sheet. Alternative valuation measures include a price-to-sales ratio of 4.67 and an EV/EBITDA of -1.44, suggesting the market is willing to pay a significant multiple of sales to acquire the revenue streams generated by the ARCUS platform. The stock has traded between a 52-week high of $8.82 and a 52-week low of $3.53, meaning the current trading price sits within a range where the upper limit suggests a potential ceiling based on recent volatility while the lower limit establishes a floor of support. The stock exhibits a beta of 1.32, meaning its price volatility is approximately 32% higher than the broader market, reflecting the heightened sensitivity of biotechnology equities to sector-specific developments and clinical trial outcomes.
Growth & Income
Revenue growth over the past year stands at an extraordinary 5261.1%, while earnings growth is listed as N/A due to the company's continued net losses, implying that top-line expansion is outpacing profitability as the company scales its commercial operations. Since the company does not pay dividends, the dividend yield is N/A and the payout ratio is 0.0%, confirming that the firm retains all earnings and cash flow to reinvest into its research and development efforts rather than distributing income to shareholders. This reinvestment strategy is standard for clinical-stage biotechnology firms that prioritize expanding their pipeline and advancing their gene editing platform over providing income to investors. The overall growth and income profile is characterized by explosive revenue expansion and a complete absence of dividend income, relying entirely on capital appreciation potential and future commercial success to generate value for equity holders.